• Your plan to assure appropriate aseptic practices and cleanroom behavior during production. Include specific steps to ensure routine supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.
• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior such as that observed during the inspection may have affected quality and sterility of your drugs.
• A corrective action and preventive action (CAPA) plan to fully remediate any contamination hazards to sterile product contact surfaces during set-up, including improved equipment design and procedures.
• A standard operating procedure (SOP) that requires routine sterilization of your RABS (b)(4) and specifies maximum use time.
• Comprehensive identification of all contamination hazards with respect to your aseptic processes, equipment, and facilities. Provide an independent risk assessment that covers, among other things, all human interactions with the ISO 5 area, equipment placement and ergonomics, air quality in the ISO 5 area and surrounding room, facility layout, personnel flow, and material flow (e.g., RABS material transfers).
• A CAPA plan, with timelines, to address the findings of the contamination hazards risk assessment. Describe how you will improve aseptic processing operation design, control, and personnel qualification.
• Provide a retrospective assessment of all media fills since January 2014. List all media fills conducted, fill date, number of units runs, number of vials rejected, number of units incubated, and number of positive units. Describe the circumstances under which any integral media fill vials were removed from each media fill batch. Explain in detail why they were rejected. Provide the final, signed summary report prepared by your firm for each media fill.
• Describe how you revised SOPs to specify when units must be rejected during commercial operations. Provide your full CAPA to ensure that units can be rejected in media fills only if appropriate and consistent with corresponding production SOPs.
• Provide a comprehensive independent review of your media fill program.
• List all batches processed during power outages since January 2015. Describe actions taken after the power failures to restore appropriate aseptic processing conditions. If you permitted continuation of batch production, describe how many units you rejected and the criteria you used to accept units following the power failure. Also, provide the related investigation report and an assessment of suitability of any batch that may have been exposed to a loss of environmental control in the aseptic processing facility.
• An update on CAPA plans you have implemented to prevent production of vials without (b)(4). Describe all steps taken to prevent recurrence of this problem. Include updated summaries of defect data from production batches, complaints (include batch number and date of manufacture), and all stability program results.
• A risk assessment that evaluates the quality and acceptability of distributed batches.
• An update on progress toward implementing in-line (b)(4) testing to detect (b)(4).
• A comprehensive independent review and remediation of your systems used to ensure thorough and timely investigations of deviations, complaints, defects, out-of-specification (OOS) results, and failures.
• Your updated investigation into source, root cause(s), and impact of (b)(4) and (b)(4) particles detected in your products. Extend your investigation to other batches that may also have been compromised by the same or similar particles.
• A CAPA that establishes routine review of variations in process performance and product quality, and ensures early identification of problematic trends and related events.
• Your evaluation of the effectiveness of investigations and CAPA to remediate your firm’s visual inspection program for sealed units, including pre-released vials.